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Tamoxifen has been a frontline treatment for estrogen receptor alpha (ERα)-positive breast tumors in premeno-
pausal women. However, resistance to tamoxifen occurs in many patients. ER still plays a critical role in the growth 
of breast cancer cells with acquired tamoxifen resistance, suggesting that ERα remains a valid target for treatment 
of tamoxifen-resistant (Tam-R) breast cancer. In an effort to identify novel regulators of ERα signaling, through a 
small-scale siRNA screen against histone methyl modifiers, we found WHSC1, a histone H3K36 methyltransferase, 
as a positive regulator of ERα signaling in breast cancer cells. We demonstrated that WHSC1 is recruited to the ERα 
gene by the BET protein BRD3/4, and facilitates ERα gene expression. The small-molecule BET protein inhibitor 
JQ1 potently suppressed the classic ERα signaling pathway and the growth of Tam-R breast cancer cells in culture. 
Using a Tam-R breast cancer xenograft mouse model, we demonstrated in vivo anti-breast cancer activity by JQ1 
and a strong long-lasting effect of combination therapy with JQ1 and the ER degrader fulvestrant. Taken together, 
we provide evidence that the epigenomic proteins BRD3/4 and WHSC1 are essential regulators of estrogen receptor 
signaling and are novel therapeutic targets for treatment of Tam-R breast cancer.
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Introduction
Estrogen signaling is crucial for the development of 
normal mammary gland and breast cancer. Estrogen 
binds to and activates estrogen receptors (ERs), result-
ing in expression of genes involved in cell proliferation 
and survival. By blocking estrogen binding to ER alpha 
(ERα), the selective ER modulator, tamoxifen remains 
a frontline treatment for ERα-positive breast cancer [1]. 
However, eventually many tumors develop tamoxifen 
resistance. Interestingly, ERα is still important for the 
growth of breast cancer cells with acquired drug resis-
tance. For instance, recent chromatin immunoprecipita-
tion (ChIP)-seq analysis on primary breast tumors from 
patients clearly shows that ERα is still recruited to chro-
matin in drug-resistant breast cancer [2]. Moreover, in 
the absence of estrogen, epidermal growth factor could 
induce AP-1-dependent ERα genomic targets [3]. There-
fore, there is an urgent need to develop novel treatments 
to further suppress ER signaling in Tam-R breast cancer. 
Recent data show that mTOR inhibition is effective in 
overcoming hormone resistance [4]. However, mTOR 
inhibition is associated with several side effects, limiting 
its use in patients who must take it for a long time. Com-
binations of HDAC inhibitor vorinostat and tamoxifen 
also showed some effect in reversing hormone resistance 
[5]. In this study, we are exploring a novel strategy to 
overcome endocrine resistance by shutting down expres-810
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sion of the ER gene itself.
Results
WHSC1 regulates ERα gene expression 
Recent progress has shown that histone-modifying en-
zymes and coregulators play important roles in the reg-
ulation of gene expression [6-8]. In this study, we were 
interested in understanding how histone modifications, 
particularly histone methylation, regulate ERα signaling 
in breast cancer cells. To this end, we performed a small-
scale siRNA screen to identify epigenomic enzymes in-
volved in estrogen signaling. We knocked down histone 
methyltransferases (HMTs) or demethylases (HDMTs) 
individually in MCF7 cells by siRNA, and determined 
the expression levels of ERα and its target genes GREB1 
and pS2. We focused on the HMTs and HDMTs that 
target lysine residues, because the diverse roles of his-
tone lysine methylation in gene expression have been 
well established. The role of 29 HMTs and 18 HDMTs 
in estrogen signaling was tested by knockdown using 
individual siRNAs. Supplementary information, Figure 
S1 shows the mRNA levels of ERα and its target gene 
GREB1. Knockdown of SMYD3 led to an increased 
level of GREB1 mRNA, while knockdown of three 
HMTs, ASH1L, SETD7 and WHSC1, and two HDMTs, 
KDM4A and KDM7C reduced GREB1 mRNA level by 
> 60%. Similar effects were observed for pS2 gene ex-
pression (data not shown). ERα mRNA levels were also 
significantly reduced in these samples, indicating that 
these epigenomic enzymes are critical for ERα and its 
target gene expression. We confirmed the reduction of 
ERα protein levels by western blot analysis as shown in 
Figure 1A. 
WHSC1 encodes a HMTs that methylates histone 
H3K36 [9, 10]. Methylation of H3K36 is a key histone 
mark for transcription elongation. WHSC1 was initially 
found to be deleted in Wolf-Hirschhorn syndrome (WHS), 
which is a malformation syndrome associated with a 
hemizygous deletion of the distal short arm of chromo-
some 4. Later studies revealed that WHSC1 is significant-
ly overexpressed in many cancers including breast cancer 
[11, 12]. Importantly, its expression is associated with 
tumor aggressiveness and bad prognosis in several breast 
cancer studies [13, 14]. However, the underlying molec-
ular mechanism of its role in breast cancer development 
remains unknown. Therefore, we focused on WHSC1 for 
further study.
Using three individual WHSC1 siRNAs, we confirmed 
the essential role of WHSC1 in expression of ERα and its 
target genes (Figure 1B and 1C). Interestingly, WHSC1 
mRNA levels were increased by two-fold in MCF7 cells 
treated with estradiol, indicating that WHSC1 itself is 
an ERα-regulated gene (Figure 1D), forming a positive 
Figure 1 WHSC1 regulates ERα gene expression. (A) Confirmation of siRNA screening results by western blot analysis. Five 
genes were selected from the siRNA screening. The protein levels of ERα and SRC-3 were measured by western blot anal-
ysis. (B) Knockdown of WHSC1 by three different siRNAs all decreased mRNA and protein levels of ERα in MCF7 cells. (C) 
Knockdown of WHSC1 reduced the expression of ERα target gene pS2 in MCF7 cells. 10 nM of estradiol (E2) was added 24 h 
before cell harvest. (D) Enhanced expression of WHSC1 by treatment of 10 nM E2 for 24 h in MCF7 cells. mRNA levels of 
ERα and WHSC1 were measured by RT-qPCR. *P < 0.05 by a two-tailed t-test. (E) Correlation of ERα mRNA and WHSC1 
mRNA levels in a subset of the TCGA breast cancer samples.Qin Feng et al.
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feedback regulatory loop. In support of this, we found a 
positive correlation in mRNA levels between WHSC1 
and ERα in ER-positive patients in the TCGA database, 
particularly in luminal-A-type of breast tumors (Figure 
1E). 
WHSC1 and BRD3/4 coordinately regulate ERα expres-
sion and function
Because WHSC1 does not contain a DNA-binding do-
main, it cannot bind directly to the ERα gene promoter/
enhancer to regulate its transcription. To investigate how 
WHSC1 activates ERα gene expression, we searched the 
Epicome database (http://epicome.org), a mass spectrom-
etry-based proteomics database generated by the Nuclear 
Receptor Signaling Atlas (NURSA) [15, 16], to identify 
WHSC1-interacting proteins. BRD3 and BRD4, two 
bromodomain-containing proteins, are at the top of a list 
of potential WHSC1-interacting proteins (Supplemen-
tary information, Figure S2A). Their association with 
WHSC1 was confirmed by immunoprecipitation/western 
blot analysis using either exogenously expressed or en-
dogenous proteins. As shown in Figure 2A-2C, BRD3 
and BRD4 were co-immunoprecipitated with WHSC1 
protein and vice versa, but another BET family protein, 
BRD2, did not interact significantly with WHSC1. Sim-
ilar interaction was detected between endogenous BRDs 
and WHSC1 in MCF7 cells (Supplementary information, 
Figure S2), and this is in agreement with a recent report 
of an interaction between WHSC1 and BRD4 in MEF 
cells [17]. 
BRD3 and BRD4 belong to the BET (bromodomain 
and extraterminal domain) family of proteins. In humans, 
there are four BET proteins including BRD2, BRD3, 
BRD4, and BRDT [18]. BET family members contain 
two bromodomain and one extraterminal domain. The 
bromodomain specifically recognizes acetylated lysine 
residues on the histone tails. BRD3 and BRD4 are im-
plicated in the transcription elongation process by asso-
ciation with the PAF1 complex and the pTEFb complex, 
respectively [19]. BRD4 also regulates the expression of 
G1 cell cycle genes [20]. We next determined the domain 
responsible for the interaction between WHSC1 and 
BRD3/4 by deletion mapping. As shown in Supplemen-
tary information, Figure S2D and S2E, BRD4 interacts 
with WHSC1 through its N-terminal 470 amino acids, 
which contains two bromodomains. Interestingly, treat-
ment of cells with JQ1 failed to disrupt the interaction 
between WHSC1 and BRD4, suggesting that BRD4 can 
bind to WHSC1 and acetylated lysine simultaneously 
(Supplementary information, Figure S2F). 
Given the key role of WHSC1 in ERα gene expres-
sion and the physical association between WHSC1 and 
BRD3/4, we hypothesized that WHSC1 is recruited to 
the ERα gene promoter by BRD3/4 which binds directly 
to acetylated histone tails and subsequent methylation of 
K36 on histone H3 by WHSC1, then could facilitate the 
transcription elongation of the ERα gene. To test this hy-
pothesis, we asked whether BRD3/4 are required for the 
expression of ERα and its target genes. As shown in Fig-
ure 2D, simultaneous knockdown of BRD3 and BRD4 
dramatically reduced the mRNA levels of ERα and pS2, 
indicating that BRD3 and BRD4 are crucial for the ex-
pression of ERα. 
To further test the above hypothesis, BRD3 and 
BRD4 genes were knocked down in MCF7 cells, and 
the recruitment of WHSC1 to the ERα gene and the lev-
el of histone H3 K36 methylation were determined by 
ChIP-qPCR assay. As shown in Figure 2E, knockdown 
of BRD3/4 dramatically reduced the recruitment of 
WHSC1 to the ERα gene and the levels of H3K36me2 
and H3K36me3 were both significantly reduced, sug-
gesting that BRD3/4 functions as a scaffold to recruit 
WHSC1, which promotes the transcription elongation of 
the ERα/ESR1 gene. 
In our model shown in Figure 2F, BET proteins 
(BRD3/4) recognize acetylated lysine residues on histone 
tails in the ERα/ESR1 gene promoter. After recruitment 
to the ERα gene by interacting with BRD3/4, WHSC1 
methylates H3K36 and subsequently increases tran-
scription elongation of ERα. On the other hand, estrogen 
stimulates the expression of WHSC1, forming a positive 
feedback regulatory loop. Interestingly, we also found 
that WHSC1 and BRD4 are potent coactivators for ER in 
an ERE-luciferase gene reporter assay (Supplementary 
information, Figure S3A). Taken together, our results in-
dicate that WHSC1 is a key regulator of ER signaling, as 
it is not only a positive epigenomic regulator of ER gene 
expression, but also a coactivator for ER itself. 
Small-molecule inhibitors have been recently devel-
oped and published for the BET family of proteins. For 
instance, JQ1, an acetylated lysine analog, has been re-
ported in recent studies to be a potent BET inhibitor and 
can be used to treat a number of cancers including multi-
ple myeloma and acute myeloid leukemia [21-23]. Based 
on our results, we tested whether JQ1 can suppress ERα 
expression. As shown in Figure 2G, treatment of MCF7 
cells with JQ1 significantly reduced the mRNA levels of 
ERα and its target genes pS2, GREB1, and Cyclin D1, 
but not other breast cancer genes such as FoxA1, SRC-3, 
and Her2 (Supplementary information, Figure S3B). An-
other bromodomain inhibitor I-BET had a similar effect, 
although at a slightly higher concentration (Figure 2H). 
Similar experiments were performed on prostate cancer 
LNCaP cells. Interestingly, androgen receptor mRNA 812
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levels were not altered upon JQ1 treatment, indicating 
that the suppression of ERα expression by JQ1 is selec-
tive (Supplementary information, Figure S3C).
JQ1 inhibits growth of Tam-R breast cancer cells 
Next, we investigated whether the BRD3/4 inhibitor 
JQ1 inhibits growth of breast cancer cells. We treated 
parental MCF7 cells and a Tam-R derivative with differ-
ent doses of JQ1 or vehicle control. As shown in Figure 
3A, JQ1 potently inhibited the growth of Tam-R MCF7 
cells, while it only moderately inhibited the growth of 
parental MCF7 cells at a concentration of 0.2 µM (At a 
higher concentration of 0.5 µM, JQ1 also inhibited pa-
rental MCF7 cell growth.). We further tested three more 
ER-positive breast cancer cell lines including T47D, 
MCF7 RN, and ZR75-1 cells. We found that JQ1 inhibit-
ed the growth of all of these breast cancer cell lines, with 
higher efficacy toward the Tam-R cells. Interestingly, 
JQ1 also inhibited four estrogen-deprivation-resistant 
(mimics aromatase inhibitor resistance) lines (Supple-
mentary information, Figure S4A). Simlar to MCF7 
cells, JQ1 downregulated ERα mRNA levels in MCF7 
Figure 2 WHSC1 and BRD3/4 coordinately regulate ERα expression and function. (A) Co-immunoprecipitation (co-IP) of 
WHSC1 and BRD proteins from transiently transfected 293T cells. HA-tagged WHSC1 or empty vector was transiently trans-
fected to 293T cells for 48 h. The whole-cell lysate was cleared and immunoprecipitated with anti-HA antibody. Input, 2.5%. (B) 
Co-IP of endogenous WHSC1 and BRD proteins from HeLa nuclear extract. Input, 2.5%. (C) Reciprocal co-IP of endogenous 
WHSC1 and BRD proteins from HeLa nuclear extract. Input, 2.5%. (D) Knockdown of BRD3 and BRD4 reduced expression 
of ERα and its target gene pS2 in MCF7 cells. Error bars indicate SEM. *P < 0.01 by t-test. (E) Loss of BRD3/4 abolished the 
recruitment of WHSC1 to ERα gene. ChIP was performed in MCF7 cells treated with BRD3/4 siRNA or control siRNA for 2 
days. Primer pair A locates next to promoter region and primer pair B locates in the coding region of ERα. Each IP was dupli-
cated and average values were shown. Error bars indicate SEM. *P < 0.05 by t-test. (F) A hypothetical model of regulation of 
ERα gene expression by WHSC1 and BRD3/4. (G) Bromodomain inhibitor JQ1 efficiently reduced the expression of ERα and 
its target genes in MCF7 cells. Cells were treated with JQ1 for 24 h before harvest. (H) Another Bromodomain inhibitor I-BET 
had similar function in suppressing ERα expression. MCF7 cells were treated with I-BET for 24 h before harvest.Qin Feng et al.
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RN and ZR75-1 cells. The ERα dominant-negative 
splicing variant ERΔ7 was similarly downregulated [24] 
(Supplementary information, Figure S4B and S4C). 
Our ChIP-qPCR analysis provided further evidence 
that disruption of BRD3/4/WHSC1/ERα axis by JQ1 
suppressed ERα gene expression. As shown in Figure 
3B, overall, the levels of histone modifications mark-
ing active promoters, such as acetylated histone H3 and 
H3K4me3, were significantly lower on the ERα gene 
promoter in Tam-R MCF7 cells, likely due to lack of oth-
er key transcriptional factor(s). JQ1 treatment in Tam-R 
cells eliminated the recruitment of BRD3/4 and WHSC1 
to the ERα gene promoter, and dramatically reduced the 
level of H3K4me3 and H3K36me3, two histone marks 
of transcription activation. In parental MCF7 cells, the 
recruitment of BRD3/4 and WHSC1 was still maintained 
at relatively high levels, although it was reduced by JQ1. 
BRD3 and BRD4 mRNA levels were not reduced (actu-
ally increased) by JQ1, while WHSC1 was reduced by 
JQ1 both at the mRNA and protein levels (Figure 3C and 
3D). 
We next wished to understand why Tam-R breast 
cancer cells are more sensitive to JQ1. Knockdown of 
WHSC1 alone reduced the ERα mRNA levels similarly 
in both parental and Tam-R breast cancer cells, and inhib-
ited the growth of parental and Tam-R MCF7 cells simi-
larly (Supplementary information, Figure S4D and S4E). 
This result suggests that WHSC1 is an important regula-
tor of ERα gene expression and cell growth, but does not 
cause extra JQ1 sensitivity in Tam-R cells. However, we 
noticed that when cells were treated with JQ1 for up to 3 
days, ERα mRNA was persistantly suppressed in Tam-R 
MCF7 cells (Figure 4A). In contrast, in parental MCF7 
cells, ERα mRNA level was abolished initially, but re-
covered after prolonged treatment (Figure 4A). More-
over, JQ1 was reported to inhibit MYC signaling in pre-
vious studies [21, 25, 26]. Thus, we measured expression 
of MYC in JQ1-treated MCF7 cells. As shown in Figure 
4A, MYC mRNA level responded to JQ1 treatment sim-
ilarly to ER in parental and Tam-R MCF7 cells. These 
results demonstrate that ERα and MYC are JQ1 target 
genes in Tam-R MCF7 cells, and that sustained sup-
Figure 3 JQ1 inhibits growth of Tam-R cells. (A) JQ1 efficiently inhibited the growth of Tam-R MCF7 breast cancer cells as 
determined by MTS assay. Error bars indicate SEM. (B) ChIP assay to determine the level of histone modifications and re-
cruitment of BRD3/4 and WHSC1 to ERα promoter. MCF7 parental and Tam-R cells were treated with DMSO (Veh) or 0.2 M 
of JQ1 for 24 h before cell harvest. Primer Pair A (shown in Figure 2E) was used for qPCR analysis. Error bars were shown 
as SEM. (C) Expression of BRDs and WHSC1 in 0.2 µM JQ1-treated MCF7 cells. (D) Western blot analysis of ERα, BRDs, 
and WHSC1 proteins from 0.2 µM JQ1-treated MCF7 cells.814
Targeting epigenomic factors for Tam-resistant breast cancer npg
Cell Research | Vol 24 No 7 | July 2014
pression of ERα and MYC by JQ1 probably contributes 
to its more potent anticancer activity on Tam-R breast 
cancer cells. To gain more mechanistic insight into this 
observation, we found that GATA3, a key regulator of 
ER gene expression [27], is highly expressed in parental 
MCF7 cells, but not in Tam-R cells (Figure 4B and 4C). 
In parental MCF7 cells, GATA3 expression is further in-
creased by JQ1 treatment (Figure 4B). When we knocked 
down GATA3 using siRNA, the parental MCF7 cells be-
came more sensitive to JQ1 treatment (Figure 4E). Thus, 
our results suggest that other key transcription factors, 
such as GATA3 in parental MCF7 cells, could have con-
tributed to the JQ1 resistance with prolonged treatment. 
A decrease in such factors (Figure 4B) might contribute 
to epigenomic environmental changes on the ERα pro-
moter, resulting in greater JQ1 sensitivity in Tam-R lines.
To determine the global signaling pathways that are 
altered by JQ1 in addition to ER and MYC, microarray 
analysis was performed on Tam-R MCF7 cells treated 
with vehicle or 0.2 µM of JQ1. When applying a thresh-
old of log2 < −0.2 or log2 > 0.2, we identified 652 down-
regulated genes and 219 upregulated genes in JQ1-treat-
ed cells (Figure 5A). Supplementary information, Table 
S1A lists all the genes upregulated or downregulated in 
major biological pathways by KEGG pathway analysis. 
Figure 5B shows the biological pathways negatively af-
fected by JQ1. Among them, the cell cycle is an import-
ant pathway being affected since cell cycle-related gene 
expression was significantly altered by JQ1 treatment 
(Supplementary information, Figure S5A). Consistent 
with this observation, we found by flow cytometry anal-
ysis that Tam-R MCF7 cells were arrested in G1 phase 
after JQ1 treatment for 24 h, while parental cells were 
arrested in G1 phase after > 48 h of JQ1 treatment (Fig-
ure 5C). Moreover, using these JQ1 target genes, we 
generated a JQ1-regulated gene signature using the same 
method as previously described [28]. Using a compendi-
um of several expression array studies, we scored human 
breast tumors based on the manifestation of the JQ1 gene 
signature. As shown in Figure 5D, in ER-positive tumors 
(N = 682), high JQ1 signature activity was associated 
with better patient outcome (log-rank P = 0.001), while 
in ER-negative tumors (N = 309), no survival association 
was found. These data further support the functional sig-
nificance of JQ1 in ER signaling in breast cancer. 
After 2 days of JQ1 treatment, Tam-R cells began to 
die, suggesting that prolonged cell cycle arrest may in-
duce apoptosis (Figure 3A). This was confirmed by the 
appearance of cleaved PARP-1 protein in Tam-R MCF7 
cells (Supplementary information, Figure S5B). In con-
Figure 4 GATA3 is a potential factor to reg-
ulate JQ1 sensitivity in MCF7 cells. (A) JQ1 
suppressed both ERα and MYC signaling 
pathways in Tam-R MCF7 cells. Parental and 
Tam-R MCF7 cells were treated with 0.2 µM 
of JQ1 for different days, and mRNA levels of 
ERα and MYC were analyzed by RT-qPCR. (B) 
Expression of GATA3 in MCF7 parental and 
Tam-R cells after JQ1 treatment. (C) Compar-
ison of GATA3 protein levels by western blot 
analysis in MCF7 parental and Tam-R cells. (D) 
Knockdown of GATA3 by siRNA reduces ERα 
gene expression. (E) Knockdown of GATA3 
by siRNA enhances JQ1 inhibition function in 
MCF7 parental cells. All error bars were shown 
as SEM.Qin Feng et al.
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trast, parental MCF7 cells did not undergo apoptosis 
(Supplementary information, Figure S5B). 
JQ1 inhibits tumor growth in Tam-R xenograft mouse 
model when combined with fulvestrant therapy
Next, we sought to determine the in vivo antitumor 
activity of JQ1. Ovariectomized nude mice were trans-
planted subcutaneously with Tam-R MCF7 tumors, and 
were randomized into two groups when tumor volumes 
reached 200 mm
3. JQ1 or control vehicle was given to 
these mice by intraperitoneal injection daily. We first 
performed a pilot experiment to treat the mice for 7 days 
to test whether JQ1 could downregulate ERα expression 
in vivo. As shown in Supplementary information, Figure 
S6A, the ERα mRNA level was indeed reduced by about 
30% in JQ1-treated tumors; MYC mRNA level was not 
significantly reduced, although there was a trend. Im-
munohistochemical staining confirmed a decreased level 
of ERα protein in JQ1-treated tumors, and a reduced 
proliferation rate was observed with Ki67 and histone 
H3 phospho-Ser10 staining (Supplementary information, 
Figure S6B). This result demonstrates that JQ1 has in 
vivo anticancer activity against Tam-R breast cancer. To 
achieve an optimal drug response in vivo, we tested a 
combination of JQ1 and fulvestrant/ICI 182,780, an ERα 
protein degrader, in Tam-R MCF7 xenograft tumors. 
While single treatment of JQ1 or fulvestrant moderate-
ly inhibited tumor growth, the combination of JQ1 and 
fulvestrant showed a synergistic antitumor activity in the 
Tam-R tumors. In the vehicle-treated group, the volumes 
of all the tumors quickly tripled within 17 days, while in 
the group that received combination therapy, none of the 
tumors tripled their size after 40 days of treatment, and 
only about half of the tumors tripled after a prolonged 
Figure 5 Cellular pathways targeted by JQ1. (A) Heatmap of expression levels for the genes differentially expressed upon 
treatment with JQ1. Tam-R MCF7 cells were treated with 0.2 µM of JQ1 or vehicle (DMSO) for 24 h before harvest for mi-
croarray analysis. (B) Biological pathways were identified by microarray analysis. KEGG pathways were determined by the 
Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov) based on the gene list 
that is downregulated by JQ1. (C) Tam-R MCF7 cells are more sensitive to JQ1-induced G1 cell cycle arrest. Cells were fixed 
and stained with propidium iodide (PI) before being analyzed by flow cytometry. (D) Association of the gene expression sig-
nature of JQ1 treatment with breast cancer patient survival. For ER-positive and ER-negative subsets, the differences in risk 
between tumors, according to degree of manifestation of the JQ1 gene signature, is compared using Kaplan-Meier plots (top 
third, “strong manifestation”; bottom third, “weak manifestation”; middle third, “intermediate manifestation”).816
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treatment (90 days) (Figure 6A). Time-to-tumor tripling 
from the four groups of treatment was compared using 
the generalized Wilcoxon test as shown in Supplemen-
tary information, Figure S6C. Although JQ1-treated 
animals lose weight initially and then regain it, gener-
ally there is no difference among the four groups in the 
baseline weights, indicating that JQ1 is well tolerated by 
mice (Figure 6B). By western blot analysis, the protein 
levels of ERα were dramatically downregulated in the 
tumors that received combination therapy of fulvestrant 
and JQ1 (Figure 6C). Immunohistochemical staining for 
Ki67 and histone H3 phospho-Ser10 confirmed that the 
combination therapy potently inhibited the tumor cell 
proliferation (Figure 6D).
Discussion
Epigenetics is defined as heritable changes caused 
by mechanisms other than changes in DNA sequence, 
including DNA methylation, histone modifications, and 
noncoding RNA. Epigenomic proteins such as chromatin 
regulators have emerged as novel therapeutic targets for 
cancer. For instance, DNA methylase inhibitors, such as 
Figure 6 A combination therapy of JQ1 and fulvestrant in Tam-R xenograft mouse model. (A) Ovariectomized mice bearing 
Tam-R-established MCF7 tumors were randomized (on day 0) into four groups of treatment: Tam+vehicle, Tam+JQ1, fulves-
trant+vehicle, and fulvestrant+JQ1, with 10 mice per group. JQ1 was administered daily at 50 mg/kg, while 5 mg fulvestrant 
was given by subcutaneous injection weekly. Tumors were harvested when they reached 1 000 mm
3 or 3 months after treat-
ment. (B) Body weight measurement for xenograft experiment shown in A. The error bars show means ± SEM. (C) Tumors 
were harvested by the end of the treatment, and western blot was performed using antibodies against ERα and cyclophilin A. 
(D) Immunohistochemical staining of ERα, Ki67, and histone H3 phospho-Ser10 in xenograft Tam-R tumors from four groups 
treated with Tam+vehicle, Tam+JQ1, fulvestrant+vehicle, or fulvestrant+JQ1.
Vidaza and Decitabine, and an HDAC inhibitor, such as 
Vorinostat, have been used clinically in treating hema-
tological malignancies [29]. Specific inhibitors against 
H3K79 methylase hDOT1L and H3K27 methylase EZH2 
also are being developed for treatment of a variety of 
cancers [30-32]. The small-molecule inhibitor of epig-
enomic reader bromodomain JQ1 has shown potent anti-
cancer activity in hematological cancer by targeting the 
MYC pathway. JQ1 is also thought to be effective in a 
subset of human lung adenocarcinoma cell lines by inhib-
iting the expression of an oncogenic transcriptional fac-
tor FOSL1 [33]. In a previous report, breast cancer cell 
lines only show modest sensitivity to JQ1 [34]. In agree-
ment with that observation, we found that the growth of 
the parental MCF7 and T47D cells was only partially 
inhibited by JQ1 at high concentrations. Strikingly, the 
Tam-R cells are more sensitive to JQ1 treatment. In our 
JQ1 treatment experiment, the ER mRNA level in MCF7 
parental cells initially was suppressed significantly but 
returned to a normal level after prolonged treatment. 
MYC mRNA levels were only slightly changed by JQ1 
in MCF7L parental cells. In contrast, in Tam-R cells, 
both ER and MYC mRNA levels were consistently sup-Qin Feng et al.
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pressed by JQ1 even after 3 days of treatment. Our result 
provides an explanation for the increased JQ1 sensitivity 
of Tam-R breast cancer cells compared to parental cells, 
and further indicates that JQ1 targets both ER ad MYC 
pathways in Tam-R cells. More importantly, JQ1 shows 
in vivo anticancer activity in suppressing the Tam-R 
breast cancer growth in the xenograft mouse model. A 
combination treatment of fulvestrant and JQ1 more effec-
tively downregulated ERα and inhibited in vitro and in 
vivo tumor growth, providing a new potential approach 
for treating Tam-R and ERα-dependent breast cancer.
Materials and Methods
Small-scale siRNA screening
A customized small siRNA library contains individual Stealth 
RNAi siRNAs (Life Technologies) targeting 29 histone lysine 
methyltransferases and 18 histone lysine demethylases. All siR-
NAs used in this study were transfected to MCF7 cells at the final 
concentration of 20 nM using Lipofectamin RNAiMAX reagent. 
Cell culture and transfection
MCF7, MCF7 RN, T47D, and ZR75-1 cells were maintained 
in RPMI 1640 medium supplemented with 10% FCS. MCF7 cells 
were initially obtained from Dr Marc Lippman in 1985 at the Na-
tional Cancer Institute, Bethesda, MD. T47D cells were purchased 
from ATCC. MCF7 RN cells were initially obtained from Dr Rob-
ert Nicholson [35]. The Tam-R lines were established from a long-
time treatment of 100 nM 4-hydroxy tamoxifen (4-HT) (Sigma) 
until cell growth was resumed. The parental cells were cultured in 
RPMI1640 supplemented with 10% of FCS, whereas their Tam-R 
derivative line was cultured in phenol red-free medium containing 
10% charcoal-dextran-stripped FCS and 100 nM of 4-HT. All cell 
lines were authenticated once the resistance was established, and 
mycoplasma contamination is tested once every 6 months. For 
estradiol-induced experiments, MCF7 cells were maintained in 
phenol red-free medium containing 10% charcoal-dextran-stripped 
FCS until hormone addition. Fugene 6 transfection reagent (Roche) 
was used for transient overexpression experiments. All siRNAs 
used in this study were individual Stealth RNAi siRNAs from 
Life Technologies, and transfected at the final concentration of 20 
nM. Lipofectamin RNAiMAX reagent was used for all the siR-
NA transfections. The mammalian expression vector of WHSC1/
MMSET (pCEFL-MMSET-II) and its control vector plasmids 
were kindly provided by Dr Zhenkun Lou at Mayo Clinic [36]. 
The six different mammalian expression vectors of BRD4 used for 
deletion mapping in Supplementary information, Figure S2D were 
obtained from Addgene. 
Co-IP and western blot analysis
Co-IP experiments were done to determine the interaction 
between WHSC1 and BRD proteins. Two days after transient 
transfection, 293T cells were harvested and washed with ice-cold 
phosphate-buffered saline before being disrupted with lysis buffer 
(50 mM Tris, 100 mM NaCl, 0.1% NP-40, 50 mM NaF, 1 mM 
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml of 
aprotinin, 0.5 µg/ml of leupeptin, and 0.7 µg/ml of pepstatin). 0.8 
mg of protein lysates was incubated with 5 µl of anti-HA antibody 
(Roche) at 4 °C for 4 h, followed by the addition of 10 µl of pro-
tein G slurry (Santa Cruz Biotechnology) for 1 h. Endogenous IP 
and co-IP were performed using nuclear extract generated from 
HeLa cells as previously described [37]. After three washes with 
lysis buffer, the immunoprecipitated proteins were separated by 
SDS-PAGE and analyzed by western blot. The antibodies used in 
co-IP and western blot are anti-BRD2 (Bethyl Labs, A302-583A), 
anti-BRD3 (Bethyl Labs, A302-368A), anti-BRD4 (Bethyl Labs, 
A301-985A50), anti-WHSC1 (Abcam, ab75359), anti-β-actin 
(Sigma, A2228), anti-ERα (Santa Cruz Biotechnology, sc-543), 
and anti-cyclophilin A (Cell Signaling Technology, 2175S). The 
specificity of the BRD antibodies was confirmed by IP/western 
blot analysis (Supplementary information, Figure S2B). The vali-
dation profiles of all the antibodies are available from their compa-
ny websites. 
Chromatin IP
The ChIP-IT Express kit (Active Motif) was used for ChIP 
assay in this study following the manufacturer’s protocol. The 
additional antibodies used in ChIP assay were rabbit IgG (Santa 
Cruz Biotechnology, sc-2027), anti-acetyl-histone H3 (Millipore, 
06-599), anti-H3K36me2 (Active Motif, 39255), anti-H3K4me3 
(Active Motif, 39159), and anti-H3K36me3 (Active Motif, 
61101). These antibodies are all ChIP grade and have been vali-
dated by their companies. The ChIP PCR primers for amplification 
of ERα/ESR1 gene next to the promoter region (A) are: Forward, 
5′-CCCACTCAACAGCGTGTCT-3′; Reverse, 5′-CTGCAG-
GAAAGGCGACAG-3′. The ChIP primers for amplification of 
ERα gene in the coding region (B) are: Forward, 5′-GAAGAAG-
CATGGGTAAATGTCA-3′; Reverse, 5′-TCAGCCCTGAAC-
CCAGTG-3′. 
RNA isolation and reverse transcription-qPCR analysis
Total RNA was extracted with TriReagent (Molecular Research 
Center) (for siRNA screening) or RNeasy Mini Kit (Qiagen). To 
measure the relative mRNA levels, real-time reverse transcrip-
tion-PCR (RT-PCR) was performed in an Applied Biosystems 
7500 fast real-time PCR system (Applied Biosystems, Foster City, 
CA). The primers for gene expression assays were designed using 
online Roche website: https://www.roche-applied-science.com/
sis/rtpcr/upl/index.jsp. The primers for amplication of total ERα: 
Forward, 5′-ATCCACCTGATGGCCAAG-3′; Reverse, 5′-GCTC-
CATGCCTTTGTTACTCA-3′. The primers for amplification of 
specifically ERΔ7: Forward, 5′-TGCTGGCTACATCATCTCG-
GTT-3′; Reverse, 5′-CCATGCCTTTGTTACAGAATTAAGCA-3′ 
[24]. The SensiFast SYBR one-step Kit (Bioline) was used for 
RT-qPCR analysis. For all RT-qPCR experiments in this study, 
samples were duplicated and the error bars were shown as SEM. 
Correlation analysis and microarray analysis
For the correlation analysis shown in Figure 1E, gene expres-
sion and clinical data were downloaded from the TCGA Breast 
Cancer [38]. Pearson correlation between WHSC1 and ESR1 was 
computed using the R-statistical system within the following sub-
types of breast cancer: Luminal A, Luminal B, Her2, and ER posi-
tive. For microarray analysis, the RNA was extracted with RNeasy 
Mini Kit (Qiagen), and the array was performed on GeneChip 
Human Gene 1.0 ST Array (Affymetrix) at Asuragen Inc. (Austin, 818
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TX) with triplicated samples. A heatmap was built using the gene 
expression for the genes differentially expressed upon treatment 
with JQ1 when a threshold of log2 < −0.2 or log2 > 0.2 was ap-
plied. Gene expression was transformed by subtracting the mean 
value and dividing by SD for each individual gene. A heatmap was 
generated using the R-statistical system. Raw microarray data can 
be accessed at Gene Expression Omnibus (GEO), with accession 
number GSE49124.
JQ1 signature analysis
For the “compendium” data set of nine separate breast tumor 
expression profiling data sets for survival analysis, gene transcrip-
tion profiling data sets (all on Affymetrix U133 array, A set, and 
all with DMFS as an outcome measure) were previously obtained 
from previous studies and consolidated into one data set [39]. 
Genes within each data set were first normalized to SD from the 
median, where multiple human array probe sets referenced the 
same gene, the probe set with the highest variation was used to 
represent the gene. To score each human breast tumor profile, for 
similarity to the gene signature of JQ1-treated cells, we derived 
a “t-score” metric for each human tumor in relation to the ex-
perimental signature, similar to what we have done in previous 
analyses [28, 40]; briefly, the t-score was defined for each external 
profile as the two-sided t-statistic comparing, within the profile, 
the average of the genes high in the signature with the average of 
the genes low in the signature.
MTS assay
Breast cancer cells were seeded at a density of 2 × 10
3 cells per 
well in flat-bottomed 96-well plates (day 0) and their growth was 
measured on days 1, 2, 3, 5, and 7 after JQ1 treatment. Cell media 
were changed every 2 days.
 CellTiter 96 AQueous One Solution 
Reagent (Promega) was added to each well following the manu-
facturer’s instructions. After 1 h of incubation, the cell viability 
was determined by measuring the absorbance at 490 nm using the 
Multiskan FC microplate photometer (Thermo Scientific). For all 
the MTS assays done in this study, samples were treated in qua-
druplicate and error bars were shown as SEM. 
Apoptosis assay
Parental and Tam-R MCF7 cells were treated with various 
dosages (0.2, 0.5, 1 µM) of JQ1 for 2 days followed by being 
harvested for western blot. The cleaved (89 kDa, C terminus) and 
full-length (116 kDa) forms of PARP-1 protein were detected by 
PARP-1 antibody (Santa Cruz Biotechnology, sc-8007, dilution 
1:200). 
In vivo Tam-R breast cancer xenograft studies and immuno-
histochemistry
The antitumor effect of JQ1 and JQ1/fulvestrant was evaluated 
in Tam-R breast cancer xenograft mouse model. Briefly, tamoxifen 
citrate-treated 4-5-week-old ovariectomized athymic mice were 
subcutaneously implanted with Tam-R breast tumor fragments 
at the hypogastrium area. Three-five weeks later when the tumor 
size reaches 150-200 mm
3, mice were randomized into four treat-
ment groups by simple randomization method, totally 10 mice per 
group. The allocation started from the first to the fourth group, and 
then from the fourth to the first group for the next round. Unless 
any animals die from an unknown reason, no animal has been ex-
cluded from the study. JQ1 or DMSO (vehicle) was administered 
daily at 50 mg/kg with 10% hydroxypropyl beta-cyclodextrin solu-
tion as a carrier, while 5 mg fulvestrant was given by subcutaneous 
injection weekly [41]. Tumors were monitored and tumor volumes 
and body weight were measured twice a week. Blind measure-
ments were carried out to avoid unconscious biases. Tumors were 
harvested for molecular studies after 3 months of treatment or 
when they reached the size of 1 000 mm
3. Small pieces of the tu-
mors were fixed and embedded in paraffin, and additional materi-
als were kept at –80 °C. H&E staining was performed to examine 
the overall structure of the tumors, and the cell proliferation was 
determined by immunohistochemical staining of Ki67 and phos-
phorylated histone H3 at Ser10. The antibodies used were histone 
H3 phospho-Ser10 (Millipore 06-570, 1:300), Ki67 (Dako M7240, 
1:200), and ERα (Vector Laboratories VP-E613, 1:200). Other 
tumor parts were used for RNA extraction and protein preparation. 
All in vivo animal studies were conducted under a protocol ap-
proved by Institutional Animal Care and Use Committees (IACUC) 
at the Baylor College of Medicine.
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